Read Friday's C.E.O.'s blog - plans to uplist to national exchange - no additional funding required.
Becton Dickinson news expected soon.
Follow the company on Twitter: @AmarantusBio .... 8,538 followers
Sentiment: Strong Buy
AMBS will outperform MNKD by 300% over the next three months. No contest.
MNKD is overvalued.
20,000 shares. why not?
Best op in the market for substantial returns.
Read today's post on the AMBS board by riskreward168.
He met with the company's C.E.O. yesterday at the Aegis Capital Investor's Conference held in Las Vegas. He posted one post regading LymPro and one post regarding MANF.
Worth the time.
The company's patented drug, MANF, could offer a potential cure for a myriad of diseases including diabetes.
Most undervalued stock in the market. Buy a few shares before it gaps higher.